THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NASDAQ:RPRX) (PCX:RPRX) today released interim findings from its study of Proellex™ in the treatment of endometriosis. To date 34 women of the 39 enrolled have completed three months of dosing. Data from these women demonstrate that treatment with the highest dosage of Proellex (50 mg) achieved statistically significant pain reduction compared to treatment with Lucrin® (Lupron®), the current pharmaceutical standard of care for the treatment of endometriosis.
